Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11988221 | 0.84 | TP53 (0.36) | TP53 | |
| SCHEMBL24045337 | 0.77 | TP53 (0.34) | TP53 | |
| SCHEMBL11485258 | 0.77 | TP53 (0.31) | TP53 | |
| SCHEMBL28061025 | 0.74 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL28093154 | 0.72 | TP53 (0.39) | TP53 | |
| SCHEMBL29213145 | 0.72 | TP53 (0.34) | TP53 | |
| SCHEMBL18503251 | 0.71 | HRH3 (0.36) | — | |
| SCHEMBL18503335 | 0.71 | HRH3 (0.36) | — | |
| SCHEMBL18503212 | 0.71 | HRH3 (0.36) | — | |
| SCHEMBL18503255 | 0.71 | HRH3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0301393-B1 | 1,4-DISUBSTITUTED 1-AZOLYL-3,3-DYMETHYLBUTANE DERIVATIVES | BAYER AG (DE) | 1991-08-14 | — | — | EP | claimed |
| US-4968712-A | PHYTOPATHOGENS, AGRICULTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | claimed |
| CN-112368641-B | Photosensitive resin composition, photosensitive sheet, cured film thereof, method for producing cured film, and electronic component | 东丽株式会社 | 2025-05-02 | — | — | CN | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
| US-20210317114-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-10-14 | — | — | US | disclosed |
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-26 | — | — | US | disclosed |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | NOVARTIS AG (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-07-13 | — | — | US | disclosed |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2012-08-02 | — | — | US | disclosed |
| US-20110200587-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-18 | — | — | US | disclosed |
| US-4968712-A | PHYTOPATHOGENS, AGRICULTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| US-4968712-A | PHYTOPATHOGENS, AGRICULTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| US-4968712-A | PHYTOPATHOGENS, AGRICULTURE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
| EP-0301393-A1 | 1,4-Disubstituted 1-azolyl-3,3-dymethylbutane derivatives | BAYER AG (DE) | 1989-02-01 | — | — | EP | disclosed |
| EP-0301393-A1 | 1,4-Disubstituted 1-azolyl-3,3-dymethylbutane derivatives | BAYER AG (DE) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200587-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | TP53 979/4885 |
| US-20210363123-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | TP53 4024/4885 |
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | TP53 3809/4885 |
| US-20170196809-A1 | METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST | POLN, POLRMT, RNGTT | TP53 1075/4885 |
| US-20170275243-A1 | Lipids and Lipid Compositions for the Delivery of Active Agents | LRAT, LPAR4, LPAR1 | TP53 2248/4885 |
| US-11591304-B2 | SLC26A3 inhibitors and use thereof | SLC26A3, SLC10A2, SLC10A6 | TP53 4024/4885 |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | TP53 3428/4885 |
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | TP53 300/4885 |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | TP53 4051/4885 |
| US-20120196845-A1 | QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRNA5 | TP53 3595/4885 |
| US-20210317114-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | IL4, IL2, IL4I1 | TP53 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.